ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0424

The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort
Abstract Number: 0425

Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)
Abstract Number: 0426

The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis
Abstract Number: 0427

Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study
Abstract Number: 0428

Difficult to Treat Spondyloarthritis: Patients with a High Biologic Switch Rate and the Factors Influencing It; A Real World as Clinic Experience
Abstract Number: 0429

No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis
Abstract Number: 0430

The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis
Abstract Number: 0431

Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
Abstract Number: 0432

Predictive Factors of Eosinophilic Granulomatosis with Polyangiitis Long-term Evolution: Data from a European Cohort
Abstract Number: 0433

Clustering of Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis – Using a Pre-processed Harmonised Dataset
Abstract Number: 0434

Sex Based Differences in Cardiovascular Conditions Associated with Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Analysis of the National Inpatient Sample
Abstract Number: 0435

Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes
Abstract Number: 0436

Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study
Abstract Number: 0437

Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Abstract Number: 0438

Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].